H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s top-line findings from its Phase 1/2 STAAR study, H.C. Wainwright reaffirmed its Buy rating and $10 price target on the company on June 25.

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

\\

Adults with Fabry disease were treated with isaralgagene civaparvovec (ST-920 or isa-vec), an alpha-galactosidase A gene therapy based on an adeno-associated virus. According to H.C. Wainwright, isa-vec is possibly the best-in-class, one-time gene therapy for Fabry disease. The firm cited improvements in quality of life, stabilization of renal function, termination of enzyme replacement treatment, and long-term alpha-Gal A expression as proof of the therapy’s promise.

In light of these encouraging outcomes, Sangamo Therapeutics Inc. (NASDAQ:SGMO) is getting ready to submit a biologics license application as early as the first quarter of 2026, which would facilitate a commercial launch in the second half of the same year.

One of the leading biotechnology companies in gene editing and gene therapy, Sangamo Therapeutics Inc. (NASDAQ:SGMO) leverages its proprietary zinc finger nuclease technology to develop novel therapies for cancer and genetic illnesses.

While we acknowledge the potential of SGMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.